151 related articles for article (PubMed ID: 35018520)
41. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy.
Bloch J; Rixe O; Meric JB; Delgado A; Khayat D
Curr Med Res Opin; 2005 Nov; 21(11):1763-71. PubMed ID: 16307696
[TBL] [Abstract][Full Text] [Related]
42. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M
Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
[TBL] [Abstract][Full Text] [Related]
43. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Ithimakin S; Theeratrakul P; Laocharoenkiat A; Nimmannit A; Akewanlop C; Soparattanapaisarn N; Techawattanawanna S; Korphaisarn K; Danchaivijitr P
Support Care Cancer; 2020 Nov; 28(11):5335-5342. PubMed ID: 32128615
[TBL] [Abstract][Full Text] [Related]
44. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.
Annemans L; Strens D; Lox E; Petit C; Malonne H
Support Care Cancer; 2008 Aug; 16(8):905-15. PubMed ID: 17965891
[TBL] [Abstract][Full Text] [Related]
45. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Brygger L; Herrstedt J;
Expert Opin Drug Saf; 2014 Oct; 13(10):1407-22. PubMed ID: 25196083
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Cubeddu LX; Pendergrass K; Ryan T; York M; Burton G; Meshad M; Galvin D; Ciociola AA
Am J Clin Oncol; 1994 Apr; 17(2):137-46. PubMed ID: 8141105
[TBL] [Abstract][Full Text] [Related]
47. Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5-hydroxytryptamine type 3 antagonists.
Babaoglu MO; Bayar B; Aynacioglu AS; Kerb R; Abali H; Celik I; Bozkurt A
Clin Pharmacol Ther; 2005 Dec; 78(6):619-26. PubMed ID: 16338277
[TBL] [Abstract][Full Text] [Related]
48. Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.
Mukhopadhyay S; Dutta P; Banerjee S; Bhattacharya B; Biswas S; M Navari R
Future Oncol; 2021 Jun; 17(16):2041-2056. PubMed ID: 33792376
[TBL] [Abstract][Full Text] [Related]
49. Ondansetron is safe and effective for prehospital treatment of nausea and vomiting by paramedics.
Salvucci AA; Squire B; Burdick M; Luoto M; Brazzel D; Vaezazizi R
Prehosp Emerg Care; 2011; 15(1):34-8. PubMed ID: 21091329
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
51. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
52. Ondansetron in the control of chemotherapy-induced and radiotherapy-induced emesis in children with malignancies.
Zoubek A; Kronberger M; Puschmann A; Gadner H
Anticancer Drugs; 1993 Dec; 4 Suppl 2():17-21. PubMed ID: 8136511
[TBL] [Abstract][Full Text] [Related]
53. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Eliasen A; Dalhoff K; Mathiasen R; Schmiegelow K; Rechnitzer C; Schelde AB; Perwitasari DA; Tsuji D; Brok J
Crit Rev Oncol Hematol; 2020 May; 149():102939. PubMed ID: 32259776
[TBL] [Abstract][Full Text] [Related]
54. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Holdsworth MT; Raisch DW; Winter SS; Chavez CM
Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172
[TBL] [Abstract][Full Text] [Related]
55. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
Billio A; Morello E; Clarke MJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
[TBL] [Abstract][Full Text] [Related]
56. A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women.
Drögemöller BI; Wright GEB; Trueman J; Shaw K; Staub M; Chaudhry S; Miao F; Higginson M; Groeneweg GSS; Brown J; Magee LA; Whyte SD; West N; Brodie SM; Jong G'; Israels S; Berger H; Ito S; Rassekh SR; Sanatani S; Ross CJD; Carleton BC
Biomed Pharmacother; 2022 Apr; 148():112684. PubMed ID: 35149390
[TBL] [Abstract][Full Text] [Related]
57. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
[TBL] [Abstract][Full Text] [Related]
58. Ondansetron in the treatment of nausea and vomiting induced by chemotherapy. Portuguese Ondansetron Study Group.
Ribiero MM; de Faria L; dos Reis F; Fráguas A; de Matos E; Uva S; Ribeiro I; Brandão A; Ribeiro M; Batarda M
Anticancer Drugs; 1993 Dec; 4 Suppl 2():23-7. PubMed ID: 8136512
[TBL] [Abstract][Full Text] [Related]
59. Prospective evaluation of ondansetron for undifferentiated nausea and vomiting in the prehospital setting.
Warden CR; Moreno R; Daya M
Prehosp Emerg Care; 2008; 12(1):87-91. PubMed ID: 18189184
[TBL] [Abstract][Full Text] [Related]
60. A randomized, open-label non-inferiority study to compare palonosetron and ondansetron for prevention of acute chemotherapy-induced vomiting in children with cancer receiving moderate or high emetogenic chemotherapy.
Jain S; Kapoor G; Koneru S; Vishwakarma G
Support Care Cancer; 2018 Sep; 26(9):3091-3097. PubMed ID: 29564625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
